{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T16:35:19Z","timestamp":1764174919657,"version":"build-2065373602"},"reference-count":175,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T00:00:00Z","timestamp":1598486400000},"content-version":"vor","delay-in-days":57,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005111","name":"Rigshospitalet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005111","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1053\/j.seminhematol.2020.08.001","type":"journal-article","created":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T21:46:26Z","timestamp":1598564786000},"page":"102-114","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Optimal approach to the treatment of young adults with acute lymphoblastic leukemia in 2020"],"prefix":"10.1053","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0578-3887","authenticated-orcid":false,"given":"Cecilie Utke","family":"Rank","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kjeld","family":"Schmiegelow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2020.08.001_bib0001","unstructured":"US Department of Health and Human Services: Closing the gap: research and care imperatives for adolescents and young adults with cancer. Available at:https:\/\/www.cancer.gov\/types\/aya\/research\/ayao-august-2006.pdf\/. Accessed February 4, 2020"},{"issue":"5","key":"10.1053\/j.seminhematol.2020.08.001_bib0002","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1200\/JCO.2003.02.053","article-title":"Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials","volume":"21","author":"Boissel","year":"2003","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1053\/j.seminhematol.2020.08.001_bib0003","doi-asserted-by":"crossref","first-page":"1954-","DOI":"10.1182\/blood.V104.11.1954.1954","article-title":"Difference in outcome of adolescents with acute lymphoblastic leukemia (ALL) enrolled in pediatric (AIEOP) and adult (GIMEMA) protocols","volume":"104","author":"Testi","year":"2004","journal-title":"Blood"},{"issue":"12","key":"10.1053\/j.seminhematol.2020.08.001_bib0004","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/sj.leu.2403538","article-title":"Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands","volume":"18","author":"de Bont","year":"2004","journal-title":"Leukemia"},{"issue":"7","key":"10.1053\/j.seminhematol.2020.08.001_bib0005","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/cncr.22189","article-title":"Treatment outcome in young adults and children >10 years of age with acute lymphoblastic leukemia in Sweden: a comparison between a pediatric protocol and an adult protocol","volume":"107","author":"Hallbook","year":"2006","journal-title":"Cancer"},{"issue":"3","key":"10.1053\/j.seminhematol.2020.08.001_bib0006","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/pbc.20749","article-title":"Adolescents with acute lymphoblastic leukaemia: outcome on UK national paediatric (ALL97) and adult (UKALLXII\/E2993) trials","volume":"48","author":"Ramanujachar","year":"2007","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"10.1053\/j.seminhematol.2020.08.001_bib0007","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/blood-2008-01-130237","article-title":"What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies","volume":"112","author":"Stock","year":"2008","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.seminhematol.2020.08.001_bib0008","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.3324\/haematol.12466","article-title":"Acute lymphoblastic leukemia in adolescents and young adults in Finland","volume":"93","author":"Usvasalo","year":"2008","journal-title":"Haematologica"},{"issue":"5","key":"10.1053\/j.seminhematol.2020.08.001_bib0009","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/ajh.23149","article-title":"Adolescents and young adults with acute lymphoblastic leukemia have a better outcome when treated with pediatric-inspired regimens: systematic review and meta-analysis","volume":"87","author":"Ram","year":"2012","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1053\/j.seminhematol.2020.08.001_bib0010","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/leu.2017.265","article-title":"Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia","volume":"32","author":"Toft","year":"2018","journal-title":"Leukemia"},{"issue":"14","key":"10.1053\/j.seminhematol.2020.08.001_bib0011","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2018-10-881961","article-title":"A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403","volume":"133","author":"Stock","year":"2019","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2020.08.001_bib0012","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/leu.2014.229","article-title":"Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia","volume":"29","author":"DeAngelo","year":"2015","journal-title":"Leukemia"},{"issue":"24","key":"10.1053\/j.seminhematol.2020.08.001_bib0013","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1200\/JCO.2017.76.8192","article-title":"Intensified therapy of acute lymphoblastic leukemia in adults: report of the randomized GRAALL-2005 clinical trial","volume":"36","author":"Huguet","year":"2018","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1053\/j.seminhematol.2020.08.001_bib0014","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1182\/blood.V122.21.839.839","volume":"122","author":"G\u00f6kbuget","year":"2013","journal-title":"Blood"},{"issue":"22","key":"10.1053\/j.seminhematol.2020.08.001_bib0015","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1182\/blood-2018-01-827949","article-title":"Thromboembolism in acute lymphoblastic leukemia: results of NOPHO ALL2008 protocol treatment in patients aged 1 to 45 years","volume":"131","author":"Rank","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2020.08.001_bib0016","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1200\/JCO.19.02208","article-title":"Asparaginase-associated pancreatitis in acute lymphoblastic leukemia: results from the NOPHO ALL2008 treatment of patients 1-45 years of age","volume":"38","author":"Rank","year":"2020","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1053\/j.seminhematol.2020.08.001_bib0017","doi-asserted-by":"crossref","first-page":"e27300","DOI":"10.1002\/pbc.27300","article-title":"Comparing osteonecrosis clinical phenotype, timing, and risk factors in children and young adults treated for acute lymphoblastic leukemia","volume":"65","author":"Mogensen","year":"2018","journal-title":"Pediatr Blood Cancer"},{"issue":"9","key":"10.1053\/j.seminhematol.2020.08.001_bib0018","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1200\/JCO.2016.70.7836","article-title":"Genetic basis of acute lymphoblastic leukemia","volume":"35","author":"Iacobucci","year":"2017","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1053\/j.seminhematol.2020.08.001_bib0019","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa1403088","article-title":"Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia","volume":"371","author":"Roberts","year":"2014","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1053\/j.seminhematol.2020.08.001_bib0020","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1182\/blood-2017-06-743252","article-title":"Philadelphia chromosome-like acute lymphoblastic leukemia","volume":"130","author":"Tasian","year":"2017","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.seminhematol.2020.08.001_bib0021","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.clml.2017.03.299","article-title":"Philadelphia chromosome-like acute lymphoblastic leukemia","volume":"17","author":"Pui","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1053\/j.seminhematol.2020.08.001_bib0022","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1182\/bloodadvances.2019000163","article-title":"Clinical diagnostics and treatment strategies for Philadelphia chromosome-like acute lymphoblastic leukemia","volume":"4","author":"Harvey","year":"2020","journal-title":"Blood Adv"},{"issue":"4","key":"10.1053\/j.seminhematol.2020.08.001_bib0023","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1200\/JCO.2016.69.0073","article-title":"High frequency and poor outcome of Philadelphia chromosome-like acute lymphoblastic leukemia in adults","volume":"35","author":"Roberts","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2020.08.001_bib0024","article-title":"Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913","author":"Chiaretti","year":"2020","journal-title":"Haematologica"},{"issue":"12","key":"10.1053\/j.seminhematol.2020.08.001_bib0025","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1056\/NEJMra035092","article-title":"Developmental pharmacology\u2013drug disposition, action, and therapy in infants and children","volume":"349","author":"Kearns","year":"2003","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1053\/j.seminhematol.2020.08.001_bib0026","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1002\/cncr.22338","article-title":"Assessing the health care needs of adolescent and young adult cancer patients and survivors","volume":"107","author":"Zebrack","year":"2006","journal-title":"Cancer"},{"issue":"4","key":"10.1053\/j.seminhematol.2020.08.001_bib0027","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1089\/jayao.2015.0005","article-title":"The age conundrum: a scoping review of younger age or adolescent and young adult as a risk factor for clinical distress, depression, or anxiety in cancer","volume":"4","author":"Lang","year":"2015","journal-title":"J Adolesc Young Adult Oncol"},{"issue":"6","key":"10.1053\/j.seminhematol.2020.08.001_bib0028","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.3109\/10428194.2011.559668","article-title":"Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases","volume":"52","author":"Raponi","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1053\/j.seminhematol.2020.08.001_bib0029","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"issue":"16","key":"10.1053\/j.seminhematol.2020.08.001_bib0030","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1200\/JCO.2016.69.3531","article-title":"Complete hematologic and molecular response in adult patients with relapsed\/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study","volume":"35","author":"Martinelli","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1053\/j.seminhematol.2020.08.001_bib0031","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/cncr.32558","article-title":"Blinatumomab compared with standard of care for the treatment of adult patients with relapsed\/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia","volume":"126","author":"Rambaldi","year":"2020","journal-title":"Cancer"},{"issue":"9","key":"10.1053\/j.seminhematol.2020.08.001_bib0032","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1053\/j.seminhematol.2020.08.001_bib0033","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1182\/bloodadvances.2019000874","article-title":"Blinatumomab consolidation and maintenance therapy in adults with relapsed\/refractory B-precursor acute lymphoblastic leukemia","volume":"4","author":"Rambaldi","year":"2020","journal-title":"Blood Adv"},{"issue":"36","key":"10.1053\/j.seminhematol.2020.08.001_bib0034","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1200\/JCO.2016.67.3301","article-title":"Phase I\/phase II study of blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"34","author":"von Stackelberg","year":"2016","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1053\/j.seminhematol.2020.08.001_bib0035","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1038\/leu.2017.41","article-title":"Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL","volume":"31","author":"Duell","year":"2017","journal-title":"Leukemia"},{"issue":"8","key":"10.1053\/j.seminhematol.2020.08.001_bib0036","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1053\/j.seminhematol.2020.08.001_bib0037","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/cncr.32116","article-title":"Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study","volume":"125","author":"Kantarjian","year":"2019","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2020.08.001_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2019.106283","article-title":"Impact of minimal residual disease status in patients with relapsed\/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial","volume":"88","author":"Jabbour","year":"2020","journal-title":"Leuk Res"},{"issue":"20","key":"10.1053\/j.seminhematol.2020.08.001_bib0039","doi-asserted-by":"crossref","first-page":"4044","DOI":"10.1002\/cncr.31720","article-title":"Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage","volume":"124","author":"Jabbour","year":"2018","journal-title":"Cancer"},{"issue":"suppl_1","key":"10.1053\/j.seminhematol.2020.08.001_bib0040","doi-asserted-by":"crossref","first-page":"3806-","DOI":"10.1182\/blood-2019-129018","volume":"134","author":"Sasaki","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1053\/j.seminhematol.2020.08.001_bib0041","first-page":"1321-","article-title":"Interim data from a phase 1 study evaluating pyrrolobenzodiazepine-based antibody drug conjugate ADCT-402 (loncastuximab tesirine) targeting CD19 for relapsed or refractory B-cell acute lymphoblastic leukemia","volume":"130","author":"Jain","year":"2017","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2020.08.001_bib0042","doi-asserted-by":"crossref","first-page":"S263","DOI":"10.1016\/j.clml.2017.07.030","article-title":"Global registration trial of efficacy and safety of CTL019 in pediatric and young adult patients with relapsed\/refractory (R\/R) acute lymphoblastic leukemia (ALL): update to the interim analysis","volume":"17","author":"Buechner","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"10.1053\/j.seminhematol.2020.08.001_bib0043","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"10.1053\/j.seminhematol.2020.08.001_bib0044","doi-asserted-by":"crossref","first-page":"895-","DOI":"10.1182\/blood-2018-99-112599","article-title":"Updated analysis of the efficacy and safety of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory (R\/R) acute lymphoblastic leukemia","volume":"132","author":"Grupp","year":"2018","journal-title":"Blood"},{"issue":"16","key":"10.1053\/j.seminhematol.2020.08.001_bib0045","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"issue":"9967","key":"10.1053\/j.seminhematol.2020.08.001_bib0046","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet (London, England)"},{"issue":"5","key":"10.1053\/j.seminhematol.2020.08.001_bib0047","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1053\/j.seminhematol.2020.08.001_bib0048","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13045-020-00856-8","article-title":"Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia","volume":"13","author":"Dai","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"4","key":"10.1053\/j.seminhematol.2020.08.001_bib0049","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/bjh.12778","article-title":"SWOG S0910: a phase 2 trial of clofarabine\/cytarabine\/epratuzumab for relapsed\/refractory acute lymphocytic leukaemia","volume":"165","author":"Advani","year":"2014","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1053\/j.seminhematol.2020.08.001_bib0050","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/ejh.12154","article-title":"Administration of alemtuzumab and G-CSF to adults with relapsed or refractory acute lymphoblastic leukemia: results of a phase II study","volume":"91","author":"Gorin","year":"2013","journal-title":"Eur J Haematol"},{"issue":"2","key":"10.1053\/j.seminhematol.2020.08.001_bib0051","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood-2012-04-418640","article-title":"Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study","volume":"120","author":"Messinger","year":"2012","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminhematol.2020.08.001_bib0052","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1158\/0008-5472.CAN-14-1849","article-title":"BH3 inhibitor sensitivity and Bcl-2 dependence in primary acute lymphoblastic leukemia cells","volume":"75","author":"Alford","year":"2015","journal-title":"Cancer Res"},{"issue":"11","key":"10.1053\/j.seminhematol.2020.08.001_bib0053","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1182\/blood-2016-09-738070","article-title":"Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia","volume":"129","author":"Frismantas","year":"2017","journal-title":"Blood"},{"issue":"suppl_1","key":"10.1053\/j.seminhematol.2020.08.001_bib0054","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood-2019-126977","article-title":"Safety and efficacy of venetoclax in combination with navitoclax in adult and pediatric relapsed\/refractory acute lymphoblastic leukemia and lymphoblastic lymphoma","volume":"134","author":"Lacayo","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2020.08.001_bib0055","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13045-020-00905-2","article-title":"Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions","volume":"13","author":"Samra","year":"2020","journal-title":"J Hematol Oncol"},{"key":"10.1053\/j.seminhematol.2020.08.001_bib0056","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1200\/EDBK_280175","article-title":"Recent advances in managing acute lymphoblastic leukemia","volume":"40","author":"DeAngelo","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"6","key":"10.1053\/j.seminhematol.2020.08.001_bib0057","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21062193","article-title":"The current genomic and molecular landscape of Philadelphia-like acute lymphoblastic leukemia","volume":"21","author":"Shiraz","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"11-12","key":"10.1053\/j.seminhematol.2020.08.001_bib0058","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1101\/gad.307504.117","article-title":"JAK2 is dispensable for maintenance of JAK2 mutant B-cell acute lymphoblastic leukemias","volume":"32","author":"Kim","year":"2018","journal-title":"Genes Dev"},{"issue":"25","key":"10.1053\/j.seminhematol.2020.08.001_bib0059","doi-asserted-by":"crossref","first-page":"e413","DOI":"10.1200\/JCO.2012.47.6770","article-title":"Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia","volume":"31","author":"Weston","year":"2013","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1053\/j.seminhematol.2020.08.001_bib0060","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.3324\/haematol.2013.095372","article-title":"Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion","volume":"98","author":"Lengline","year":"2013","journal-title":"Haematologica"},{"issue":"12","key":"10.1053\/j.seminhematol.2020.08.001_bib0061","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1182\/blood-2006-11-056754","article-title":"Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801","volume":"109","author":"DeAngelo","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2020.08.001_bib0062","article-title":"Clinical experience with venetoclax combined with chemotherapy for relapsed or refractory T-cell acute lymphoblastic leukemia","author":"Richard-Carpentier","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"10.1053\/j.seminhematol.2020.08.001_bib0063","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1158\/2159-8290.CD-14-0353","article-title":"Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199","volume":"4","author":"Chonghaile","year":"2014","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1053\/j.seminhematol.2020.08.001_bib0064","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41375-018-0201-2","article-title":"The MCL1-specific inhibitor S63845 acts synergistically with venetoclax\/ABT-199 to induce apoptosis in T-cell acute lymphoblastic leukemia cells","volume":"33","author":"Li","year":"2019","journal-title":"Leukemia"},{"issue":"9","key":"10.1053\/j.seminhematol.2020.08.001_bib0065","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1182\/blood-2017-07-794214","article-title":"Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia","volume":"131","author":"Bride","year":"2018","journal-title":"Blood"},{"issue":"10","key":"10.1053\/j.seminhematol.2020.08.001_bib0066","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1182\/blood-2014-12-618900","article-title":"AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia","volume":"126","author":"Moradi Manesh","year":"2015","journal-title":"Blood"},{"issue":"14","key":"10.1053\/j.seminhematol.2020.08.001_bib0067","doi-asserted-by":"crossref","first-page":"4493","DOI":"10.1158\/1078-0432.CCR-19-0551","article-title":"OBI-3424, a novel AKR1C3-activated prodrug, exhibits potent efficacy against preclinical models of T-ALL","volume":"25","author":"Evans","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1053\/j.seminhematol.2020.08.001_bib0068","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1158\/0008-5472.CAN-08-4295","article-title":"Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-cell acute lymphoblastic leukemia cells","volume":"69","author":"Rao","year":"2009","journal-title":"Cancer Res"},{"issue":"9","key":"10.1053\/j.seminhematol.2020.08.001_bib0069","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.040931","article-title":"Therapeutic targeting of notch signaling and immune checkpoint blockade in a spontaneous, genetically heterogeneous mouse model of T-cell acute lymphoblastic leukemia","volume":"12","author":"Gao","year":"2019","journal-title":"Dis Models Mech"},{"issue":"21","key":"10.1053\/j.seminhematol.2020.08.001_bib0070","doi-asserted-by":"crossref","first-page":"968-","DOI":"10.1182\/blood.V124.21.968.968","article-title":"The safety and activity of BMS-906024, a gamma secretase inhibitor (GSI) with anti-notch activity, in patients with relapsed T-cell acute lymphoblastic leukemia (T-ALL): initial results of a phase 1 trial","volume":"124","author":"Zweidler-McKay","year":"2014","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2020.08.001_bib0071","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/s41375-019-0653-z","article-title":"Therapeutic targeting of the E3 ubiquitin ligase SKP2 in T-ALL","volume":"34","author":"Rodriguez","year":"2020","journal-title":"Leukemia"},{"issue":"9","key":"10.1053\/j.seminhematol.2020.08.001_bib0072","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/ncb1464","article-title":"Leukaemic transformation by CALM-AF10 involves upregulation of Hoxa5 by hDOT1L","volume":"8","author":"Okada","year":"2006","journal-title":"Nat Cell Biol"},{"issue":"24","key":"10.1053\/j.seminhematol.2020.08.001_bib0073","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1182\/blood-2017-12-818948","article-title":"The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia","volume":"131","author":"Stein","year":"2018","journal-title":"Blood"},{"issue":"23","key":"10.1053\/j.seminhematol.2020.08.001_bib0074","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1182\/blood-2014-04-531871","article-title":"Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition","volume":"124","author":"Irving","year":"2014","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminhematol.2020.08.001_bib0075","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1038\/s41375-018-0065-5","article-title":"An \"off-the-shelf\" fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies","volume":"32","author":"Cooper","year":"2018","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2020.08.001_bib0076","series-title":"American Association for Cancer Research (AACR) Virtual Annual Meeting I","article-title":"Clinical safety and efficacy study of TruUCAR\u2122 GC027: the first-in-human, universal CAR-T therapy for adult relapsed\/refractory T-cell acute lymphoblastic leukemia (r\/r T-ALL)","author":"Wang","year":"2020"},{"issue":"3","key":"10.1053\/j.seminhematol.2020.08.001_bib0077","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/bjh.13834","article-title":"Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia","volume":"172","author":"Ravandi","year":"2016","journal-title":"Br J Haematol"},{"issue":"14","key":"10.1053\/j.seminhematol.2020.08.001_bib0078","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"G\u00f6kbuget","year":"2018","journal-title":"Blood"},{"issue":"suppl_1","key":"10.1053\/j.seminhematol.2020.08.001_bib0079","doi-asserted-by":"crossref","first-page":"3807-","DOI":"10.1182\/blood-2019-129657","article-title":"Updated results from the phase II study of hyper-CVAD in sequential combination with blinatumomab in newly diagnosed adults with B-cell acute lymphoblastic leukemia (B-ALL)","volume":"134","author":"Richard-Carpentier","year":"2019","journal-title":"Blood"},{"issue":"11","key":"10.1053\/j.seminhematol.2020.08.001_bib0080","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1056\/NEJMoa1605085","article-title":"Rituximab in B-lineage adult acute lymphoblastic leukemia","volume":"375","author":"Maury","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2020.08.001_bib0081","doi-asserted-by":"crossref","DOI":"10.1177\/2040620719849496","article-title":"Novel monoclonal antibody-based treatment strategies in adults with acute lymphoblastic leukemia","volume":"10","author":"Guerra","year":"2019","journal-title":"Ther Adv Hematol"},{"issue":"15_suppl","key":"10.1053\/j.seminhematol.2020.08.001_bib0082","doi-asserted-by":"crossref","first-page":"7041-","DOI":"10.1200\/JCO.2018.36.15_suppl.7041","article-title":"A phase 2 study of hyper-CVAD plus ofatumumab as frontline therapy in CD20+ acute lymphoblastic leukemia (ALL): updated results","volume":"36","author":"Bazarbachi","year":"2018","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.1053\/j.seminhematol.2020.08.001_bib0083","doi-asserted-by":"crossref","first-page":"4011-","DOI":"10.1182\/blood-2018-99-113712","article-title":"A novel oral histone deacetylase inhibitor chidamide is highly effective and well-tolerated in adult early T-cell precursor and Ph-like acute lymphoblastic leukemia","volume":"132","author":"Zhou","year":"2018","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminhematol.2020.08.001_bib0084","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1158\/1535-7163.MCT-18-0706","article-title":"Antileukemia effects of notch-mediated inhibition of oncogenic PLK1 in B-cell acute lymphoblastic leukemia","volume":"18","author":"Kannan","year":"2019","journal-title":"Mol Cancer Ther"},{"issue":"15_suppl","key":"10.1053\/j.seminhematol.2020.08.001_bib0085","doi-asserted-by":"crossref","first-page":"10500","DOI":"10.1200\/JCO.2018.36.15_suppl.10500","article-title":"COG AALL0434: a randomized trial testing nelarabine in newly diagnosed t-cell malignancy","volume":"36","author":"Dunsmore","year":"2018","journal-title":"J Clin Oncol"},{"issue":"S4","key":"10.1053\/j.seminhematol.2020.08.001_bib0086","first-page":"e27989","article-title":"COG AALL0434: randomized trial of escalating dose versus high dose methotrexate and nelarabine for adolescents and young adults with newly diagnosed T\u2010cell acute lymphoblastic leukemia","volume":"66","author":"Dunsmore","year":"2019","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"10.1053\/j.seminhematol.2020.08.001_bib0087","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/17474086.2017.1262757","article-title":"Nelarabine in the treatment of pediatric and adult patients with T-cell acute lymphoblastic leukemia and lymphoma","volume":"10","author":"Kadia","year":"2017","journal-title":"Expert Rev Hematol"},{"issue":"3","key":"10.1053\/j.seminhematol.2020.08.001_bib0088","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1200\/JCO.2017.74.4946","article-title":"Reduced-intensity delayed intensification in standard-risk pediatric acute lymphoblastic leukemia defined by undetectable minimal residual disease: results of an international randomized trial (AIEOP-BFM ALL 2000)","volume":"36","author":"Schrappe","year":"2018","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1053\/j.seminhematol.2020.08.001_bib0089","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S1470-2045(12)70600-9","article-title":"Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial","volume":"14","author":"Vora","year":"2013","journal-title":"Lancet Oncol"},{"issue":"15","key":"10.1053\/j.seminhematol.2020.08.001_bib0090","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1200\/JCO.2013.52.2425","volume":"32","author":"Ribera","year":"2014","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1053\/j.seminhematol.2020.08.001_bib0091","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1182\/blood-2015-03-633685","article-title":"Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232","volume":"126","author":"Borowitz","year":"2015","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminhematol.2020.08.001_bib0092","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.0580","article-title":"Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis","volume":"3","author":"Berry","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1053\/j.seminhematol.2020.08.001_bib0093","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.clml.2017.02.019","article-title":"Minimal residual disease assessment and risk-based therapy in acute lymphoblastic leukemia","volume":"17S","author":"Bassan","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"10.1053\/j.seminhematol.2020.08.001_bib0094","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1182\/blood-2017-03-735639","article-title":"High-throughput sequencing for noninvasive disease detection in hematologic malignancies","volume":"130","author":"Scherer","year":"2017","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.seminhematol.2020.08.001_bib0095","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1182\/blood-2015-07-655159","article-title":"The predictive strength of next-generation sequencing MRD detection for relapse compared with current methods in childhood ALL","volume":"126","author":"Kotrova","year":"2015","journal-title":"Blood"},{"issue":"12","key":"10.1053\/j.seminhematol.2020.08.001_bib0096","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1182\/blood-2017-09-806521","article-title":"Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL","volume":"131","author":"Wood","year":"2018","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2020.08.001_bib0097","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1182\/blood-2016-03-707562","article-title":"Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"128","author":"Short","year":"2016","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.seminhematol.2020.08.001_bib0098","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1182\/blood-2013-09-529008","article-title":"UKALLXII\/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia","volume":"123","author":"Fielding","year":"2014","journal-title":"Blood"},{"issue":"12","key":"10.1053\/j.seminhematol.2020.08.001_bib0099","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1182\/blood-2009-12-261586","article-title":"First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia","volume":"116","author":"Ravandi","year":"2010","journal-title":"Blood"},{"issue":"23","key":"10.1053\/j.seminhematol.2020.08.001_bib0100","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.1002\/cncr.29646","article-title":"Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"121","author":"Ravandi","year":"2015","journal-title":"Cancer"},{"issue":"3","key":"10.1053\/j.seminhematol.2020.08.001_bib0101","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1182\/bloodadvances.2016001495","article-title":"US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL","volume":"1","author":"Ravandi","year":"2016","journal-title":"Blood Adv"},{"issue":"6","key":"10.1053\/j.seminhematol.2020.08.001_bib0102","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1182\/blood-2015-03-636548","article-title":"Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia","volume":"126","author":"Kim","year":"2015","journal-title":"Blood"},{"issue":"15","key":"10.1053\/j.seminhematol.2020.08.001_bib0103","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S1470-2045(15)00207-7","article-title":"Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study","volume":"16","author":"Jabbour","year":"2015","journal-title":"Lancet Oncol"},{"issue":"15_suppl","key":"10.1053\/j.seminhematol.2020.08.001_bib0104","doi-asserted-by":"crossref","first-page":"7013-","DOI":"10.1200\/JCO.2017.35.15_suppl.7013","article-title":"Frontline hyper-CVAD plus ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: updated results of a phase II study","volume":"35","author":"Short","year":"2017","journal-title":"J Clin Oncol"},{"issue":"suppl_1","key":"10.1053\/j.seminhematol.2020.08.001_bib0105","doi-asserted-by":"crossref","first-page":"283-","DOI":"10.1182\/blood-2019-125146","article-title":"Long-term safety and efficacy of hyper-CVAD plus ponatinib as frontline therapy for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"134","author":"Short","year":"2019","journal-title":"Blood"},{"issue":"19","key":"10.1053\/j.seminhematol.2020.08.001_bib0106","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1053\/j.seminhematol.2020.08.001_bib0107","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1002\/cncr.30231","article-title":"Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a propensity score analysis","volume":"122","author":"Sasaki","year":"2016","journal-title":"Cancer"},{"issue":"4","key":"10.1053\/j.seminhematol.2020.08.001_bib0108","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.clml.2018.02.010","article-title":"Efficacy of ponatinib versus earlier generation tyrosine kinase inhibitors for front-line treatment of newly diagnosed Philadelphia-positive acute lymphoblastic leukemia","volume":"18","author":"Jabbour","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"24","key":"10.1053\/j.seminhematol.2020.08.001_bib0109","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1182\/blood-2015-02-627935","article-title":"Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia","volume":"125","author":"Chalandon","year":"2015","journal-title":"Blood"},{"issue":"23","key":"10.1053\/j.seminhematol.2020.08.001_bib0110","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1182\/blood.V126.23.81.81","article-title":"Multicenter total therapy GIMEMA LAL 1509 protocol for de novo adult Ph+ acute lymphoblastic leukemia (ALL) patients. Updated results and refined genetic-based prognostic stratification","volume":"126","author":"Chiaretti","year":"2015","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2020.08.001_bib0111","series-title":"Presented at the 24th European Hematology Association Annual Congress","article-title":"A dasatinib-blinatumomab combination for the front-line treatment of adult PH+ ALL patients. Preliminary results of the GIMEMA LAL2116 D-ALBA trial; on behalf of GIMEMA acute leukemia working party","author":"Chiaretti","year":"2019"},{"issue":"6","key":"10.1053\/j.seminhematol.2020.08.001_bib0112","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/s41409-018-0373-4","volume":"54","author":"Giebel","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1053\/j.seminhematol.2020.08.001_bib0113","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/cncr.30376","article-title":"Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease","volume":"123","author":"Issa","year":"2017","journal-title":"Cancer"},{"issue":"2","key":"10.1053\/j.seminhematol.2020.08.001_bib0114","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ajh.25338","article-title":"Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: a consensus of North American experts","volume":"94","author":"Short","year":"2019","journal-title":"Am J Hematol"},{"issue":"suppl 5","key":"10.1053\/j.seminhematol.2020.08.001_bib0115","doi-asserted-by":"crossref","first-page":"v69","DOI":"10.1093\/annonc\/mdw025","article-title":"Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Hoelzer","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2020.08.001_bib0116","doi-asserted-by":"crossref","DOI":"10.1177\/2040620720903531","article-title":"Practical guidance for the management of acute lymphoblastic leukemia in the adolescent and young adult population","volume":"11","author":"Carobolante","year":"2020","journal-title":"Ther Adv Hematol"},{"issue":"1","key":"10.1053\/j.seminhematol.2020.08.001_bib0117","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13045-019-0729-2","article-title":"Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challenges","volume":"12","author":"Soverini","year":"2019","journal-title":"J Hematol Oncol"},{"issue":"4","key":"10.1053\/j.seminhematol.2020.08.001_bib0118","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1182\/blood-2007-10-116582","volume":"111","author":"Goldstone","year":"2008","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2020.08.001_bib0119","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1182\/blood-2012-07-445098","article-title":"Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: an individual patient data meta-analysis","volume":"121","author":"Gupta","year":"2013","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2020.08.001_bib0120","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/ajh.24285","article-title":"Pediatric-inspired therapy compared to allografting for Philadelphia chromosome-negative adult ALL in first complete remission","volume":"91","author":"Seftel","year":"2016","journal-title":"Am J Hematol"},{"issue":"suppl_1","key":"10.1053\/j.seminhematol.2020.08.001_bib0121","doi-asserted-by":"crossref","first-page":"261-","DOI":"10.1182\/blood-2019-128560","volume":"134","author":"Wieduwilt","year":"2019","journal-title":"Blood"},{"issue":"16","key":"10.1053\/j.seminhematol.2020.08.001_bib0122","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1182\/blood-2014-09-599894","article-title":"Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia","volume":"125","author":"Dh\u00e9din","year":"2015","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminhematol.2020.08.001_bib0123","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1182\/blood-2011-09-377713","article-title":"Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies","volume":"120","author":"G\u00f6kbuget","year":"2012","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2020.08.001_bib0124","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1182\/blood-2016-07-726588","article-title":"Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults","volume":"129","author":"Jain","year":"2017","journal-title":"Blood"},{"issue":"18","key":"10.1053\/j.seminhematol.2020.08.001_bib0125","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.1182\/blood-2008-11-185132","article-title":"Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)","volume":"113","author":"Bassan","year":"2009","journal-title":"Blood"},{"issue":"10","key":"10.1053\/j.seminhematol.2020.08.001_bib0126","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.3324\/haematol.2018.201053","article-title":"A systematic literature review and meta-analysis of minimal residual disease as a prognostic indicator in adult B-cell acute lymphoblastic leukemia","volume":"104","author":"Bassan","year":"2019","journal-title":"Haematologica"},{"issue":"1","key":"10.1053\/j.seminhematol.2020.08.001_bib0127","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1080\/16078454.2019.1567654","article-title":"Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia","volume":"24","author":"G\u00f6kbuget","year":"2019","journal-title":"Hematology"},{"issue":"1","key":"10.1053\/j.seminhematol.2020.08.001_bib0128","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13045-019-0790-x","article-title":"Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT","volume":"12","author":"Pavl\u016f","year":"2019","journal-title":"J Hematol Oncol"},{"issue":"23","key":"10.1053\/j.seminhematol.2020.08.001_bib0129","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.1002\/cncr.32335","article-title":"Transplantation in adults with relapsed\/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study","volume":"125","author":"Jabbour","year":"2019","journal-title":"Cancer"},{"issue":"3","key":"10.1053\/j.seminhematol.2020.08.001_bib0130","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1089\/jayao.2015.0014","article-title":"Best practices in adolescent and young adult patients with acute lymphoblastic leukemia: a focus on asparaginase","volume":"4","author":"Boissel","year":"2015","journal-title":"J Adolesc Young Adult Oncol"},{"issue":"5","key":"10.1053\/j.seminhematol.2020.08.001_bib0131","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/ejh.12097","article-title":"Risk group assignment differs for children and adults 1-45 years with acute lymphoblastic leukemia treated by the NOPHO ALL-2008 protocol","volume":"90","author":"Toft","year":"2013","journal-title":"Eur J Haematol"},{"issue":"9","key":"10.1053\/j.seminhematol.2020.08.001_bib0132","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/S1470-2045(12)70274-7","article-title":"Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trial","volume":"13","author":"Mattano","year":"2012","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1053\/j.seminhematol.2020.08.001_bib0133","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1177\/1078155217701291","article-title":"Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen","volume":"24","author":"Christ","year":"2018","journal-title":"J Oncol Pharm Pract"},{"issue":"3","key":"10.1053\/j.seminhematol.2020.08.001_bib0134","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26891","article-title":"Predictors of hepatotoxicity and pancreatitis in children and adolescents with acute lymphoblastic leukemia treated according to contemporary regimens","volume":"65","author":"Denton","year":"2018","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"10.1053\/j.seminhematol.2020.08.001_bib0135","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/ejh.12600","article-title":"Toxicity profile of repeated doses of PEG-asparaginase incorporated into a pediatric-type regimen for adult acute lymphoblastic leukemia","volume":"96","author":"Aldoss","year":"2016","journal-title":"Eur J Haematol"},{"issue":"11","key":"10.1053\/j.seminhematol.2020.08.001_bib0136","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S0344-0338(98)80068-X","article-title":"Incidence and pattern of liver involvement in haematological malignancies","volume":"194","author":"Walz-Mattm\u00fcller","year":"1998","journal-title":"Pathol Res Pract"},{"issue":"5","key":"10.1053\/j.seminhematol.2020.08.001_bib0137","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1001\/jamaoncol.2017.5305","article-title":"Pediatric-inspired treatment regimens for adolescents and young adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: a review","volume":"4","author":"Siegel","year":"2018","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1053\/j.seminhematol.2020.08.001_bib0138","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1159\/000442342","article-title":"L-carnitine for treatment of pegasparaginase-induced hepatotoxicity","volume":"135","author":"Alshiekh-Nasany","year":"2016","journal-title":"Acta Haematol"},{"issue":"5","key":"10.1053\/j.seminhematol.2020.08.001_bib0139","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1016\/j.clml.2018.02.014","article-title":"L-carnitine and vitamin B complex for the treatment of pegasparaginase-induced hyperbilirubinemia","volume":"18","author":"Rausch","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10","key":"10.1053\/j.seminhematol.2020.08.001_bib0140","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1080\/10428194.2018.1435873","article-title":"Levocarnitine for asparaginase-induced hepatic injury: a multi-institutional case series and review of the literature","volume":"59","author":"Schulte","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"10.1053\/j.seminhematol.2020.08.001_bib0141","doi-asserted-by":"crossref","first-page":"e00194","DOI":"10.14309\/crj.0000000000000194","article-title":"L-carnitine and vitamin B complex for PEG-L-asparaginase-induced hepatotoxicity","volume":"6","author":"Arora","year":"2019","journal-title":"ACG Case Rep J"},{"issue":"5","key":"10.1053\/j.seminhematol.2020.08.001_bib0142","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1177\/1078155217710714","article-title":"Levocarnitine and vitamin B complex for the treatment of pegaspargase-induced hepatotoxicity: a case report and review of the literature","volume":"24","author":"Blackman","year":"2018","journal-title":"J Oncol Pharm Pract"},{"issue":"3","key":"10.1053\/j.seminhematol.2020.08.001_bib0143","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1080\/10428194.2019.1680839","article-title":"Efficacy and toxicity of reduced vs. standard dose pegylated asparaginase in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia","volume":"61","author":"Derman","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"10.1053\/j.seminhematol.2020.08.001_bib0144","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.3109\/10428194.2011.596963","article-title":"Prevention and management of asparaginase\/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel","volume":"52","author":"Stock","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"10.1053\/j.seminhematol.2020.08.001_bib0145","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1200\/JCO.2013.50.2708","article-title":"Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia","volume":"32","author":"Douer","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2020.08.001_bib0146","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1200\/JCO.18.01877","article-title":"Intermittent versus continuous PEG-asparaginase to reduce asparaginase-associated toxicities: a NOPHO ALL2008 randomized study","volume":"37","author":"Albertsen","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1053\/j.seminhematol.2020.08.001_bib0147","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2217\/ijh-2016-0002","article-title":"Erythrocyte encapsulated l-asparaginase (GRASPA) in acute leukemia","volume":"5","author":"Thomas","year":"2016","journal-title":"Int J Hematol Oncol"},{"issue":"1","key":"10.1053\/j.seminhematol.2020.08.001_bib0148","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1365-2141.2011.08588.x","article-title":"l-asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005-01 randomized trial","volume":"153","author":"Domenech","year":"2011","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1053\/j.seminhematol.2020.08.001_bib0149","doi-asserted-by":"crossref","first-page":"756","DOI":"10.3324\/haematol.2018.194175","article-title":"THROMBOTECT\u2014a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents","volume":"104","author":"Greiner","year":"2019","journal-title":"Haematologica"},{"issue":"9","key":"10.1053\/j.seminhematol.2020.08.001_bib0150","article-title":"Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia","author":"Utke Rank","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1053\/j.seminhematol.2020.08.001_bib0151","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.exphem.2007.11.010","article-title":"Retherapy using L-asparaginase with octreotide in a patient recovering from L-asparaginase-induced pancreatitis","volume":"36","author":"Suzuki","year":"2008","journal-title":"Exp Hematol"},{"issue":"3","key":"10.1053\/j.seminhematol.2020.08.001_bib0152","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1365-2141.2011.08971.x","article-title":"Does octreotide prevent L-asparaginase-associated pancreatitis in children with acute lymphoblastic leukaemia?","volume":"157","author":"Tokimasa","year":"2012","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1053\/j.seminhematol.2020.08.001_bib0153","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.1002\/phar.1460","article-title":"Successful use of octreotide as a chemoprotectant for prevention of PEG-asparaginase-induced pancreatitis","volume":"34","author":"Buie","year":"2014","journal-title":"Pharmacotherapy"},{"issue":"2","key":"10.1053\/j.seminhematol.2020.08.001_bib0154","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s12185-017-2219-z","article-title":"Prophylactic use of octreotide for asparaginase-induced acute pancreatitis","volume":"106","author":"Sakaguchi","year":"2017","journal-title":"Int J Hematol"},{"issue":"6","key":"10.1053\/j.seminhematol.2020.08.001_bib0155","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1182\/blood.V89.6.1886","article-title":"Asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia","volume":"89","author":"Parsons","year":"1997","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2020.08.001_bib0156","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/00004836-200301000-00016","article-title":"Issues in hyperlipidemic pancreatitis","volume":"36","author":"Yadav","year":"2003","journal-title":"J Clin Gastroenterol"},{"issue":"5","key":"10.1053\/j.seminhematol.2020.08.001_bib0157","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/pbc.22305","article-title":"Conservative treatment of L-asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia","volume":"54","author":"Cohen","year":"2010","journal-title":"Pediatr Blood Cancer"},{"issue":"10","key":"10.1053\/j.seminhematol.2020.08.001_bib0158","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26559","article-title":"Hypertriglyceridemia during asparaginase treatment in children with acute lymphoblastic leukemia correlates with antithrombin activity in adolescents","volume":"64","author":"Persson","year":"2017","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"10.1053\/j.seminhematol.2020.08.001_bib0159","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0231209","article-title":"Dyslipidemia at diagnosis of childhood acute lymphoblastic leukemia","volume":"15","author":"Mogensen","year":"2020","journal-title":"PloS One"},{"issue":"11","key":"10.1053\/j.seminhematol.2020.08.001_bib0160","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.3324\/haematol.2014.109413","article-title":"The toxicity of very prolonged courses of PEGasparaginase or Erwinia asparaginase in relation to asparaginase activity, with a special focus on dyslipidemia","volume":"99","author":"Tong","year":"2014","journal-title":"Haematologica"},{"issue":"15","key":"10.1053\/j.seminhematol.2020.08.001_bib0161","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1016\/j.ejca.2014.06.023","article-title":"Severe hypertriglyceridaemia during therapy for childhood acute lymphoblastic leukaemia","volume":"50","author":"Bhojwani","year":"2014","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1053\/j.seminhematol.2020.08.001_bib0162","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/pbc.26183","article-title":"Asparaginase-associated pancreatitis is not predicted by hypertriglyceridemia or pancreatic enzyme levels in children with acute lymphoblastic leukemia","volume":"64","author":"Raja","year":"2017","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"10.1053\/j.seminhematol.2020.08.001_bib0163","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.3324\/haematol.2016.160507","article-title":"Hyperlipidemia is a risk factor for osteonecrosis in children and young adults with acute lymphoblastic leukemia","volume":"102","author":"Mogensen","year":"2017","journal-title":"Haematologica"},{"issue":"5","key":"10.1053\/j.seminhematol.2020.08.001_bib0164","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1182\/blood.V97.5.1211","article-title":"Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01","volume":"97","author":"Silverman","year":"2001","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2020.08.001_bib0165","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1365-2141.2009.07712.x","article-title":"Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen","volume":"146","author":"Storring","year":"2009","journal-title":"Br J Haematol"},{"issue":"21","key":"10.1053\/j.seminhematol.2020.08.001_bib0166","doi-asserted-by":"crossref","first-page":"3915-","DOI":"10.1182\/blood.V122.21.3915.3915","article-title":"The number of peg-asparaginase doses administered is a determinant of relapse risk in adult ALL treated with a pediatric-like regimen","volume":"122","author":"Aldoss","year":"2013","journal-title":"Blood"},{"issue":"15_suppl","key":"10.1053\/j.seminhematol.2020.08.001_bib0167","doi-asserted-by":"crossref","first-page":"10005-","DOI":"10.1200\/JCO.2019.37.15_suppl.10005","article-title":"Impact of asparaginase discontinuation on outcome in childhood ALL: a report from the Children's Oncology Group (COG)","volume":"37","author":"Gupta","year":"2019","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1053\/j.seminhematol.2020.08.001_bib0168","doi-asserted-by":"crossref","first-page":"4164","DOI":"10.1182\/blood-2006-09-045351","article-title":"Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511","volume":"109","author":"Wetzler","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2020.08.001_bib0169","series-title":"Nordic Society of Paediatric Haematology and Oncology 37th Annual Meeting","article-title":"Relapse following truncation of asparaginase in NOPHO ALL2008","author":"H\u00f8jfeldt","year":"2019"},{"issue":"17","key":"10.1053\/j.seminhematol.2020.08.001_bib0170","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1200\/JCO.2011.38.9924","article-title":"Nonadherence to oral mercaptopurine and risk of relapse in Hispanic and non-Hispanic white children with acute lymphoblastic leukemia: a report from the children's oncology group","volume":"30","author":"Bhatia","year":"2012","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1053\/j.seminhematol.2020.08.001_bib0171","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1001\/jamaoncol.2015.0245","article-title":"Systemic exposure to thiopurines and risk of relapse in children with acute lymphoblastic leukemia: a Children's Oncology Group Study","volume":"1","author":"Bhatia","year":"2015","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1053\/j.seminhematol.2020.08.001_bib0172","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/leu.2009.303","article-title":"The degree of myelosuppression during maintenance therapy of adolescents with B-lineage intermediate risk acute lymphoblastic leukemia predicts risk of relapse","volume":"24","author":"Schmiegelow","year":"2010","journal-title":"Leukemia"},{"issue":"4","key":"10.1053\/j.seminhematol.2020.08.001_bib0173","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1182\/blood-2017-11-778555","article-title":"Psychosocial challenges and health-related quality of life of adolescents and young adults with hematologic malignancies","volume":"132","author":"Husson","year":"2018","journal-title":"Blood"},{"issue":"15","key":"10.1053\/j.seminhematol.2020.08.001_bib0174","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1200\/JCO.2005.03.426","article-title":"Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group","volume":"23","author":"Berg","year":"2005","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1053\/j.seminhematol.2020.08.001_bib0175","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"Gokbuget","year":"2018","journal-title":"Blood"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196320300275?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196320300275?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:26:59Z","timestamp":1758522419000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196320300275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":175,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0037196320300275"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2020.08.001","relation":{},"ISSN":["0037-1963"],"issn-type":[{"type":"print","value":"0037-1963"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimal approach to the treatment of young adults with acute lymphoblastic leukemia in 2020","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2020.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}